Law Offices of Thomas J. Lamb

  • About Our Firm
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

March 31, 2021 By Law Offices of Thomas J. Lamb, P.A.

AbstractMalignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pericardial mesothelioma, peritoneal mesothelioma, pleural mesothelioma

Malignant Pleural Mesothelioma Clinical Practice Guidelines (SEOM, 2021)

March 4, 2021 By Law Offices of Thomas J. Lamb, P.A.

Diagnosis and Staging:  Genomic studies are not recommended in routine clinical practice but may be appropriate in selected patients with malignant pleural mesothelioma (MPM), especially those with young age and family history of cancer, who may carry germline mutations in cancer susceptibility genes. Chest computed tomography (CT) scan … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Study seeks to identify biological markers that predict mesothelioma response to treatment

February 25, 2021 By Law Offices of Thomas J. Lamb, P.A.

The National Cancer Institute (NCI) has granted a $2.5 million, five-year R37 MERIT Award to Dr. Bryan Burt, associate professor of surgery and chief of the Division of General Thoracic Surgery, for his [ mesothelioma medical study ] titled, “Proteomic Determinants of Response to Checkpoint Blockade in Malignant Pleural Mesothelioma.” “Malignant … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

February 17, 2021 By Law Offices of Thomas J. Lamb, P.A.

Background:  Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

New Options Spark Sequencing and Biomarker Trials in Mesothelioma

February 11, 2021 By Law Offices of Thomas J. Lamb, P.A.

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients [ with unresectable pleural mesothelioma ], … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos, asbestos cancer, mesothelioma, mesothelioma treatments, pleural mesothelioma

Bristol’s Opdivo scores again in tough-to-treat mesothelioma, this time flying solo

February 5, 2021 By Law Offices of Thomas J. Lamb, P.A.

Last year at the World Conference on Lung Cancer, Bristol Myers Squibb made waves in mesothelioma with data showing its Opdivo – Yervoy duo could slash the risk of death in previously untreated patients. This year, it grabbed the spotlight with another survival win in the tough-to-treat disease. Saturday, solo Opdivo became the first med to show … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, Opdivo

Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in‐vitro

January 28, 2021 By Law Offices of Thomas J. Lamb, P.A.

Malignant pleural mesothelioma (MPM) is an aggressive tumour that grows in the pleural cavity. [ Malignant pleural mesothelioma (MPM) ] spheroids released in the pleural fluid can form new tumour foci. Cell–cell, cell–extracellular matrix (ECM) interactions in 2D and 3D impact malignant cell behaviour during cell adhesion, migration, proliferation … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial

January 15, 2021 By Law Offices of Thomas J. Lamb, P.A.

Background:  A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Chemo-Free Regimen Boosts OS in Mesothelioma

November 23, 2020 By Law Offices of Thomas J. Lamb, P.A.

A chemotherapy-free combination significantly improved overall survival (OS) as initial therapy for unresectable malignant pleural mesothelioma (MPM), a large randomized trial showed. Patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) had a media OS of 18.1 months versus 14.1 months for patients randomized to chemotherapy. The … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

October 16, 2020 By Law Offices of Thomas J. Lamb, P.A.

Background:  Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. Patients and … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.